Lung cancer continues to lead cancer-related deaths in the United States. During the last decade, it has become clear that somatic gene alterations can cause this deadly disease. The discovery of epidermal growth factor receptor (EGFR) somatic mutations in lung cancer has provided better understanding of tumor formation and ushered the development of tyrosine kinase inhibitors (TKIs) as a standard treatment. However, despite initial dramatic responses, resistance to TKIs emerges within 2 years. Cytosine (C) to thymine (T) single base pair change leads to a threonine to methionine (T790M) amino acid alteration in the ATP-binding pocket of the EGFR. T790M is detected in more than 50% of gefitinib/erlotinib-resistant patients. However, the precise mechanism of emergence of this mutation is not clear. Activation-induced cytidine deaminase (AID) is a B-cell-specific DNA mutator and plays an important role in immune system by creating antibody diversity. Expression and activation of AID is tightly regulated under normal conditions, but aberrant expression of AID in lymphocytes or other tissues can cause cancer by introducing chromosomal translocations and/or mutations. We hypothesize that AID can be induced by EGFR TKIs and creates T790M acquired resistant mutation in EGFR. Therefore, our specific aims are to: (1) Examine whether AID induced by EGFR TKIs leads to emergence of EGFR T790M in vitro and in vivo; and (2) Identify the mechanism by which EGFR TKIs induce AID. We believe that the experiments proposed here will provide novel insights into development of drug resistant mutations in oncogenic kinases and significantly impact care of patients with NSCLC in the near future.

Public Health Relevance

Introduction of EGFR tyrosine kinase inhibitors has revolutionized the treatment of EGFR mutant lung cancer. In spite of an initially high response rate, practically all cases acquire resistance caused by resistant mutations. Our major goal in this proposal is to identify the molecular mechanisms by which drug resistance emerges. A better understanding of lung cancer development will lead to novel therapeutic strategies in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA178301-01A1
Application #
8813049
Study Section
Special Emphasis Panel (ZCA1-SRB-C (O1))
Program Officer
Forry, Suzanne L
Project Start
2014-12-09
Project End
2016-11-30
Budget Start
2014-12-09
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$200,996
Indirect Cost
$85,481
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Jorge, Susan E; Lucena-Araujo, Antonio R; Yasuda, Hiroyuki et al. (2018) EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res 24:6548-6555
Takenaka, Tomoya; Katayama, Miku; Sugiyama, Ayaka et al. (2017) Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density. Anticancer Res 37:4779-4788
Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 protein is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem 292:18924-18936
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177
Lucena-Araujo, Antonio R; Moran, Jason P; VanderLaan, Paul A et al. (2016) De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer 99:17-22
Kobayashi, Susumu S; Vali, Shireen; Kumar, Ansu et al. (2016) Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget 7:35989-36001
Costa, Daniel B; Jorge, Susan E; Moran, Jason P et al. (2016) Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol 11:918-23

Showing the most recent 10 out of 15 publications